KLK3 and cancer: Patients diagnosed with high-risk PCa during 2006–2015, through the Cancer Registry of Norway, treated with RP 12 mo or RT 15 mo after diagnosis, and classified with high-risk disease according to the European Association of Urology (PSA >20 ng/ml or GS 8–10 or clinical tumor category 2c).